Overview
GHRP-2 (Pralmorelin) is a synthetic hexapeptide growth hormone secretagogue developed in the 1990s. It is considered one of the most potent members of the GHRP family for stimulating GH release. While it shares the mechanism of action with other GHRPs through ghrelin receptor activation, it has distinct characteristics including moderate effects on appetite and a favorable profile for GH research applications.
GHRP-2 has been utilized in clinical research as a diagnostic GH stimulant and in investigative treatment protocols for growth hormone deficiency. It exhibits a superior GH-releasing potency compared to GHRP-6 while producing fewer side effects on appetite and cortisol levels, making it a valuable tool for assessing pituitary GH reserve and exploring therapeutic applications.
Mechanism of Action
GHRP-2 acts as a potent agonist at the ghrelin receptor (GHSR-1a), stimulating growth hormone release from the pituitary. It works synergistically with GHRH analogs through activation of different signaling pathways. GHRP-2 may also have some effects on cortisol and prolactin, though less pronounced than GHRP-6. Its appetite-stimulating effects are moderate compared to GHRP-6.
The peptide binds to the GHSR-1a receptor, triggering a cascade of intracellular signaling events that ultimately lead to the synthesis and secretion of GH from somatotroph cells in the anterior pituitary gland. GHRP-2's mechanism provides a controlled and targeted approach to modulating GH levels for research purposes.
Key Benefits
- Potent GH Release
- IGF-1 Elevation
- Moderate Appetite Effects
- Potential for Sleep Research
Research & Indications
Research consistently demonstrates GHRP-2 (Pralmorelin) as one of the most potent growth hormone secretagogues available for research, producing robust GH elevations through high-affinity binding to the growth hormone secretagogue receptor (GHSR-1a) on pituitary somatotroph cells. Studies demonstrate significant and sustained elevation of insulin-like growth factor 1 (IGF-1) following GHRP-2-induced growth hormone release.
GHRP-2 has been investigated for its potential role in sleep research. Preliminary research indicates GHRP-2 may enhance slow-wave sleep (SWS) duration and quality, which is notable because this deep sleep phase naturally coincides with the largest nocturnal growth hormone secretion pulse. These sleep effects have generated interest in GHRP-2 for insomnia research, sleep architecture studies in the elderly, and investigations into the bidirectional relationship between growth hormone and sleep quality.
Dosing Protocols
Disclaimer: This information is not medical advice. Consult with a qualified healthcare professional before using GHRP-2.
Research protocols typically use 100-300 mcg administered 2-3 times daily. The peptide is often studied in combination with GHRH analogs.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| GH Release | 100-300 mcg | 2-3 times daily | Subcutaneous |
Supplies Needed
For an 8-week protocol:
- Peptide Vials: 4-6 vials of 10mg each
- Insulin Syringes (U-100): 56 syringes
- Bacteriostatic Water: 1-2 × 10mL bottles
- Alcohol Swabs: Approximately 112 swabs
Side Effects & Safety
Side effects may include increased hunger (though less pronounced than with GHRP-6), increased cortisol and prolactin levels (though generally less significant than with GHRP-6), and possible injection site reactions. It is important to monitor hormone levels and consult with a healthcare professional.
Storage & Handling
Store lyophilized GHRP-2 at -20°C. Reconstitute with bacteriostatic water and store at 2-8°C for up to 14 days.